Prof. Dr. med. Carola Berking

Lehrstuhl für Haut- und Geschlechtskrankheiten

Immune checkpoint blockade in advanced cutaneous squamous cell carcinoma: What do we currently know in 2020? (2020) Wessely A, Steeb T, Leiter U, Garbe C, Berking C, Heppt M Journal article Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversion (2020) Simon D, Tascilar K, Krönke G, Kleyer A, Zaiss M, Heppt F, Meder C, et al. Journal article Patient Perception of Mobile Phone Apps for the Care and Prevention of Sexually Transmitted Diseases: Cross-Sectional Study (2020) Jakob L, Steeb T, Fiocco Z, Pumnea T, Jakob SN, Wessely A, Rothenberger CC, et al. Journal article The COVID-19 pandemic: implications for patients undergoing immunomodulating or immunosuppressive treatments in dermatology (2020) Reinholz M, French LE, Berking C, Heppt M Journal article, Letter Patients Receiving Cytokine Inhibitors Have Low Prevalence of SARS-CoV-2 Infection (2020) Simon D, Tascilar K, Krönke G, Kleyer A, Zaiss M, Heppt F, Meder C, et al. Conference contribution Evaluation of PD-L1 Expression and HPV Genotyping in Anal Squamous Cell Carcinoma (2020) Wessely A, Heppt M, Kammerbauer C, Steeb T, Kirchner T, Flaig MJ, French LE, et al. Journal article Real-world analysis of dabrafenib plus trametinib in patients with BRAFV600-mutated melanoma brain metastases (2020) Berking C, Schadendorf D, Weichenthal M, Eigentler T, Mohr P, Schober K, Kiecker F, et al. Conference contribution Treatment Decision when there is an Indication for adjuvant Therapy for Melanoma - multicenter Real World Data (2020) Lodde G, Forschner A, Wulfken LM, Meier F, Mohr P, Kaehler KC, Schilling B, et al. Conference contribution SERIO - Side Effect Registry Immuno-Oncology Side Effect Registry for rare, severe and complex Side Effects of Immunotherapy (2020) Kramer R, Mentzer D, Erdmann M, Knauss S, Broeckelmann PJ, Hassel JC, Ugurel S, et al. Conference contribution Effectiveness of Dabrafenib plus Trametinib during the Treatment of Melanoma Patients with BRAFV600 mutated Brain Metastases (2020) Berking C, Schadendorf D, Weichenthal M, Eigentler T, Schober K, Mohr P, Kiecker F, et al. Conference contribution